Retracted Article: the Clinical Significance of Serum Scd25 As a Sensitive Disease Activity Marker for Rheumatoid Arthritis

H. Sun,Y. Wang,H. Yao,L. Wang,S. Wu,Y. Si,Y. Meng,J. Xu,Q. Wang,X. Sun,Z. Li
DOI: https://doi.org/10.1080/03009742.2019.1574890
2019-01-01
Scandinavian Journal of Rheumatology
Abstract:Objective: This study aimed to evaluate the performance and clinical significance of soluble interleukin-2 receptor-alpha chains (sCD25) as a disease activity marker in rheumatoid arthritis (RA), especially in those with negative C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR). Methods: sCD25 levels were measured by enzyme-linked immunosorbent assay. The association between sCD25 and serological features of RA, and the clinical significance of sCD25 as an RA disease activity marker, were analysed. Results: The serum levels of sCD25 in RA were significantly elevated compared to those in patients with osteoarthritis and healthy controls. sCD25 was significantly correlated with RA disease activity parameters such as ESR, CRP, tender joint counts, and 28-joint Disease Activity Score (DAS28). Furthermore, sCD25-positive RA patients were more likely to show higher disease activity (DAS28 > 5.1). The predictive value of sCD25 on high disease activity was comparable to that of CRP and ESR. In 50% of the patients with active disease but negative for CRP/ESR, sCD25 was still positive. Conclusion: sCD25 is a sensitive serum marker to evaluate RA disease activity, and it could be a promising laboratory marker to assist RA disease activity assessment in patients with active RA but negative ESR or CRP.
What problem does this paper attempt to address?